Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Exactis Innovation - Exactis*

$33 million for 2014-24
About   |   News   |   Features
Exactis Innovation

Number of partners

Partner contributions
$8.9 million

Montréal, Quebec

President and CEO
Richard Fajzel Richard Fajzel

Chief Medical Officer
Gerald BatistGerald Batist

Board chair
Maha Katabi Maha Katabi

Canada as a world-class centre for cutting-edge cancer clinical trials

The opportunity

In this new era of personalized medicine, smaller patient populations are recruited to clinical trials based on very distinct genetic or molecular biomarker indicators. Identifying the right patients for trials of new targeted agents is time-consuming and costly. There are currently no pan-Canadian cancer registries containing patient clinical data with associated tumour molecular data. Having a large clinical and molecular database of patients and their banked tumours will allow rapid identification of patient-treatment matches, resulting in faster access for patients to new treatments, an accelerated clinical development process and reduced clinical trial costs.

How Exactis is seizing the opportunity

Exactis Innovation (Exactis) is a pan-Canadian, non-profit network that provides accelerated access to clinical trials for precision cancer therapies in areas of high unmet need to patients who have their cancer molecularly profiled. Exactis’ vision is to integrate precision oncology across Canada and enable greater access to leading edge clinical trials for Canadian cancer patients. Exactis’ attracts innovative clinical trials and match Canadian patients in its network to personalized oncology treatments using state of the art molecular screening platforms. The continuum of expertise and systems that have been brought together across the Exactis network represents a critical and valuable capability for Canadian cancer patients, clinician scientists and the interaction between academia and the bio-pharmaceutical sector to accelerate precision oncology in Canada.

Among the results

  • Since its inception in 2014, Exactis has built a pan-Canadian research network of 11 sites and launched the Personalize My Treatment (PMT) platform, which collects clinical and molecular information about cancer patients, enrolled in PMT. PMT is a unique platform following patients over their disease trajectory, allowing the monitoring of disease evolution from primary tumour to acquired resistance. To date, the PMT Registry has accrued more than over 3,800 patients across 6 cancer cohorts with an expected enrollment rate of 2,500 per year going forward. 
  • As of 2018, Exactis has attained a critical participant enrollment to attract new trials into the network.  To conduct these trials, Exactis has integrated clinical and translational teams with significant experience in conducting and managing longitudinal, biopsy-led clinical studies. 
  • Three multi-centre, serial biopsy trials in colorectal and lung cancer were managed by Exactis and are in the closing/reporting stages, with promising biomarker discoveries to be published in 2019. Currently, Exactis is supporting and managing the TRAM Study, a Biomarker molecular/targeted Phase 2 study with Trametinib monotherapy for pediatric patients with low grade glioma or plexiform neurofibroma open at five academic centers in Canada that leverages the specific expertise in targeted trials (CHU Ste Justine, Montreal Children’s, CHUL, SickKids and BC Children’s Hospital).

Connect with Exactis

* (formerly known as PreThera Research)


The chances of surviving cancer are about to get better
June 19, 2017
New cancer-fighting drugs are being developed every year. But which one is the right one for you and your particular cancer? Read more